Adverum Biotechnologies, Inc.
Clinical trials sponsored by Adverum Biotechnologies, Inc., explained in plain language.
-
One shot to fight blindness? gene therapy trial aims to replace frequent eye injections
Disease control Recruiting nowThis study is testing whether a single gene therapy injection can control wet age-related macular degeneration (a leading cause of blindness) as well as or better than the current standard of care, which requires eye injections every 1-4 months. About 284 participants, both new a…
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
One shot could replace years of eye injections for leading cause of blindness
Disease control Recruiting nowThis study is testing a single gene therapy injection for wet age-related macular degeneration (AMD), a major cause of vision loss. It aims to see if this one-time treatment can work as well as or better than the current standard of frequent eye injections. The trial will enroll …
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC